Intellia Therapeutics and Novartis are expanding their cell therapy collaboration agreement to include the ex vivo development of therapies using certain ocular stem cells, according to a press release.
Novartis will be able to use these stem cells to develop CRISPR/Cas9-based products under the agreement. Intellia will receive a one-time payment of $10 million, as well as be eligible for success-based milestones and royalties.
In addition, Intellia will gain extended rights to Novartis’ lipid nanoparticle technology for genome editing applications, the release said.
“Genome editing enhancements made by CRISPR/Cas9 will enable the next generation of cell therapies. With our collaborator, Novartis, we are broadening the ex vivo application of our CRISPR/Cas9 technology from hematopoietic stem cells, or HSCs, to ocular stem cells,” John Leonard, MD, Intellia CEO and president, said in the release.